Melanotan II vs PT-141 (Bremelanotide)

Melanotan II: Synthetic melanocortin peptide with tanning, appetite-suppressive, and sexual function effects. Typical dose 250-1000 mcg. PT-141 (Bremelanotide): FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Typical dose 1000-2000 mcg. Both fall under the Cosmetic and Sexual Health categories.

Stacking Melanotan II with PT-141 (Bremelanotide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Melanotan II is typically dosed: Once daily for Tanning (loading phase); Once or twice weekly for Tanning (maintenance); As needed, 1-2 hours before activity for Sexual function enhancement. PT-141 (Bremelanotide) is typically dosed: As needed, at least 45 minutes before activity for HSDD treatment (FDA-approved dose); As needed, 45-60 minutes before activity for General sexual function enhancement.

Melanotan II: Not FDA approved. The FDA has issued warnings against the use of Melanotan II, citing it as an unregulated and potentially dangerous product. The derivative PT-141 (bremelanotide/Vyleesi) was approved for sexual dysfunction but Melanotan II itself was not pursued for approval. PT-141 (Bremelanotide): FDA approved. Bremelanotide (Vyleesi) was approved in June 2019 for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.